How much of the productivity losses among psoriasis patients are due to psoriasis

BMC Health Services Research

Risto Tuominen¹  Leena Koulu³  Mauri Leino³  Kalle Mattila³  Anssi Mustonen² 

[1] Department of Public Health, University of Turku and Primary Health Care Unit, Hospital District of Southwest Finland, Turku, Finland;Lemminkäisenkatu 1, 20014 University of Turku, Turku, Finland;Department of Dermatology, Turku University Hospital and University of Turku, Turku, Finland

关键词: Productivity;    Psoriasis;    Presenteeism;    Costs;    Absenteeism;   

Others  :  1135512
DOI  :  10.1186/s12913-015-0752-0

 received in 2014-08-11, accepted in 2015-02-17,  发布年份 2015

【 摘 要 】

Background

In previous studies, productivity losses have been measured specifically due to psoriasis or generally due to health problems in psoriasis patients. There is no information on the proportion of health related productivity losses that are due to psoriasis.

The aim of this study was to estimate the proportion of productivity losses due to psoriasis and due to other medical problems among employed psoriasis patients.

Methods

Patients visiting a tertiary level dermatological clinic during a one-year period due to psoriasis or psoriasis arthritis, who were employed, were selected to the study. A questionnaire was used to assess productivity losses during the previous month.

Results

Psoriasis accounted for 38% of the total lost productivity costs. One fifth of patients had been on sick leave (absenteeism) due to psoriasis and a third of patients worked despite being sick with psoriasis (presenteeism). Men had higher costs of presenteeism, but the costs of absenteeism due to psoriasis were lower for men than for women.

Conclusions

Productivity losses should be assessed disease specifically to avoid overestimations of the role of the disease on indirect costs. Our study shows that about a third of the lost productivity costs are due to psoriasis.

【 授权许可】

   
2015 Mustonen et al.; licensee BioMed Central.

【 参考文献 】

• [1]Raval K, Lofland JH, Waters H, Piech CT: Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol 2011, 10(2):189-96.
• [2]Mattila K, Leino M, Mustonen A, Koulu L, Tuominen R: Influence of psoriasis on work. Eur J Dermatol 2013, 23(2):208-11.
• [3]Armstrong AW, Schupp C, Wu J, Bebo B: Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One 2012, 7(12):e52935.
• [4]Chan B, Hales B, Shear N, Ho V, Lynde C, Poulin Y, et al.: Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg 2009, 13(4):192-7.
• [5]Pearce DJ, Singh S, Balkrishnan R, Kulkrani A, Fleischer AB, Feldman SR: The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006, 17(1):24-8.
• [6]Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, et al.: Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010, 24(9):1075-82.
• [7]Javitz HS, Ward MM, Farber E, Farber E, Nail L, Vallow SG: The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002, 46(6):850-60.
• [8]Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A: Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study. Eur J Dermatol 2012, 22(2):238-45.
• [9]Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, et al.: Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006, 212(2):137-44.
• [10]Raho G, Koleva DM, Garattini L, Naldi L: The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics 2012, 30(11):1005-13.
• [11]Berger K, Ehlken B, Kugland B, Augustin M: Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005, 3(7):511-8.
• [12]Jacobs P, Bissonnette R, Guenther LC: Socioeconomic burden of immune-mediated inflammatory diseases–focusing on work productivity and disability. J Rheumatol Suppl 2011, 88:55-61.
• [13]Kvamme MK, Lie E, Kvien TK, Kristiansen IS: Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology (Oxford) 2012, 51(9):1618-27.
• [14]Schmitt JM, Ford DE: Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006, 213(2):102-10.
• [15]Schultz AB, Chen CY, Edington DW: The cost and impact of health conditions on presenteeism to employers: a review of the literature. Pharmacoeconomics 2009, 27(5):365-78.
• [16]Colombo G, Altomare G, Peris K, Martini P, Quarta G, Congedo M, et al.: Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008, 4(2):559-68.
• [17]Ekelund M, Mallbris L, Qvitzau S, Stenberg B: A higher score on the dermatology life quality index. Acta Derm Venereol, Being on Systemic Treatment and Having a Diagnosis of Psoriatic Arthritis is Associated with Increased Costs in Patients with Plaque Psoriasis; 2013.
• [18]Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, et al.: The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008, 59(5):772-80.
• [19]Allen H, Bunn WB 3rd, Naim AB: The self-reported health and productivity burden of autoimmune disorders at a major self-insured employer. J Occup Environ Med 2012, 54(9):1049-63.
• [20]Brooks A, Hagen SE, Sathyanarayanan S, Schultz AB, Edington DW: Presenteeism: critical issues. J Occup Environ Med 2010, 52(11):1055-67.
• [21]Hemp P: Presenteeism: at work–but out of it. Harv Bus Rev 2004, 82(10):49-58. 155
• [22]Krol M, Brouwer W, Rutten F: Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics 2013, 31(7):537-49.
• [23]Carrascosa JM, Pujol R, Dauden E, Hernanz-Hermosa JM, Bordas X, Smadia JA, et al.: A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006, 20(7):840-5.
• [24]Finlay AY, Coles EC: The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995, 132(2):236-44.
• [25]Gosselin E, Lemyre L, Corneil W: Presenteeism and absenteeism: differentiated understanding of related phenomena. J Occup Health Psychol 2013, 18(1):75-86.
• [26]Robertson I, Leach D, Doerner N, Smeed M: Poor health but not absent: prevalence, predictors, and outcomes of presenteeism. J Occup Environ Med 2012, 54(11):1344-9.
• [27]Knies S, Candel MJ, Boonen A, Evers SM, Ament AJ, Severens JL: Lost productivity in four European countries among patients with rheumatic disorders: are absenteeism and presenteeism transferable? Pharmacoeconomics 2012, 30(9):795-807.
• [28]Braakman-Jansen LM, Taal E, Kuper IH, van de Laar MA: Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA. Rheumatology (Oxford) 2012, 51(2):354-61.
• [29]Zhang W, Anis AH: The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol 2011, 30(Suppl 1):S25-32.
• [30]Confederation of Finnish Industries. Sairauspoissaolojen hallinta. (Managing sickness absence. In Finnish) 2009. http://pda.ek.fi/www/fi/tutkimukset_julkaisut/2009/SPopas_yrityksille.pdf (Accessed 6.3.2015).
• [31]Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M: Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy 2012, 10(5):343-53.
• [32]Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, et al.: Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol 2007, 17(5):381-6.
• [33]Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Baurcier M, et al.: Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat 2011, 22(6):337-47.